Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6, 55
eCollection

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor

Affiliations

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor

Roumen Milev. Front Psychiatry.

Abstract

No abstract available

Keywords: agitation; botulinum toxin; major depressive disorder; prediction; treatment.

Comment on

Similar articles

See all similar articles

References

    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 62(6):593–60210.1001/archpsyc.62.6.617 - DOI - PubMed
    1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 62(6):617–27.10.1001/archpsyc.62.6.617 - DOI - PMC - PubMed
    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349(9064):1498–504.10.1016/S0140-6736(96)07495-8 - DOI - PubMed
    1. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord (2009) 117:S15–25.10.1016/j.jad.2009.06.042 - DOI - PubMed
    1. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord (2009) 117:S26–43.10.1016/j.jad.2009.06.041 - DOI - PubMed

LinkOut - more resources

Feedback